QUETIAPINE TEVA LP 300 mg, extended-release tablet 30 tablets, CIP 3400930265161
Active ingredients: Quetiapine fumarate, Quetiapine
Commercialized according to BDPMANSM noticeDispensing in France: Prescription only
Extended-release tablet30 tablets, CIP 3400930265161orale
Supply disruption
Package details
Original BDPM fields are shown in French.
- Official name
- QUETIAPINE TEVA LP 300 mg, comprimé à libération prolongée
- Pharmaceutical form
- comprimé à libération prolongée
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC PVDC aluminium de 30 comprimé(s)
- Marketing authorisation holder
- TEVA SANTE
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 15 Jun 2023
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
60798791CIP73026516CIP133400930265161Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| FUMARATE DE QUÉTIAPINEcomprimé | — | SA |
| QUÉTIAPINEcomprimé | 300 mg · un comprimé | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.